Do you expect continued movement away from one-stop-shop outsourcing toward deeper modality-specific expertise?
As emerging modalities reshape drug development pipelines, the criteria for choosing the right CDMO partner are evolving. In this Pharma's Almanac roundtable, Samsung Biologics' Mary Lee Schiesz weighs in on what matters most to clients today — from specialized expertise in ADCs and multispecifics to the enduring appeal of an integrated one-stop shop.
When technical capabilities are comparable, trust becomes the differentiator. Seamless project management, transparent communication, and a proven track record reduce risk and free clients to focus on what matters most: advancing their pipeline.
Read the full roundtable discussion on what defines a true partnership in modern biopharma.
As emerging modalities reshape drug development pipelines, the criteria for choosing the right CDMO partner are evolving. In this Pharma's Almanac roundtable, Samsung Biologics' Mary Lee Schiesz weighs in on what matters most to clients today — from specialized expertise in ADCs and multispecifics to the enduring appeal of an integrated one-stop shop.
When technical capabilities are comparable, trust becomes the differentiator. Seamless project management, transparent communication, and a proven track record reduce risk and free clients to focus on what matters most: advancing their pipeline.
Read the full roundtable discussion on what defines a true partnership in modern biopharma.
Share article
Related Content